carbamates has been researched along with gs-5816 in 182 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 116 (63.74) | 24.3611 |
| 2020's | 66 (36.26) | 2.80 |
| Authors | Studies |
|---|---|
| Kanda, T; Nakamoto, S; Shirasawa, H; Wu, S; Yokosuka, O | 1 |
| Brainard, DM; Freilich, B; German, P; Han, L; Lawitz, E; Link, J; Marbury, T; McNally, J; Mo, H; Rodriguez-Torres, M | 1 |
| Hubbard, H; Lawitz, E; Vizuete, J | 1 |
| Brainard, D; German, P; Kearney, BP; Mathias, A; McNally, J; Mogalian, E; Moorehead, L; Yang, CY | 1 |
| Brainard, DM; Chung, RT; Davis, MN; Doehle, B; Etzkorn, K; Everson, GT; Han, L; Hinestrosa, F; McHutchison, JG; McNally, J; Morgan, T; Nahass, RG; Rabinovitz, M; Thuluvath, PJ; Tong, M; Towner, WJ; Tran, TT; Wyles, DL | 1 |
| Brainard, DM; Doehle, B; Dore, GJ; Flamm, SL; Gane, EJ; Han, L; Kumar, S; McHutchison, JG; McNally, J; Mogalian, E; Pianko, S; Rabinovitz, M; Reddy, KR; Roberts, SK; Shiffman, ML; Stedman, CA; Strasser, SI; Towner, WJ | 1 |
| An, D; Brainard, DM; Brown, RS; Bzowej, N; Charlton, M; Curry, MP; Doehle, B; Fenkel, JM; Flamm, SL; Fontana, R; Fried, M; Korenblat, KM; Lawitz, E; McHutchison, JG; McNally, J; Muir, AJ; O'Leary, JG; Osinusi, A; Reddy, KR; Schiano, T; Schiff, E; Teperman, L | 1 |
| Abergel, A; Agarwal, K; Asselah, T; Brainard, DM; Chan, HL; Feld, JJ; Gruener, N; Hézode, C; Jacobson, IM; Lai, CL; Mangia, A; Mazzotta, F; McHutchison, JG; McNally, J; Moreno, C; Osinusi, A; Ruane, PJ; Shafran, SD; Svarovskaia, E; Towner, WJ; Tran, TT; Yoshida, E; Zeuzem, S; Zhu, Y | 1 |
| Afdhal, N; Agarwal, K; Asselah, T; Berg, T; Bourlière, M; Brainard, DM; Bräu, N; Conway, B; Cooper, C; Dvory-Sobol, H; Foster, GR; Gane, EJ; Gordon, SC; Han, L; Lawitz, E; Mangia, A; Mazzotta, F; McHutchison, JG; McNally, J; Mo, H; Osinusi, A; Patel, K; Pianko, S; Reau, N; Roberts, SK; Rosenberg, W; Ruane, P; Shiffman, ML; Stedman, CA; Sulkowski, M; Thompson, A; Towner, WJ; Tran, TT; Wang, J; Zeuzem, S | 1 |
| Asselah, T; Boyer, N; Marcellin, P; Martinot-Peignoux, M; Saadoun, D | 1 |
| Agarwal, K; Feld, J; Henry, L; Hezode, C; Hunt, S; Jacobson, I; Nader, F; Stepanova, M; Younossi, ZM; Zeuzem, S | 1 |
| Kahveci, AS; Tahan, V | 1 |
| Daniels, N; Porteny, T; Urrutia, J | 1 |
| Einecke, D | 1 |
| Brainard, DM; Gane, EJ; Hyland, RH; McHutchison, JG; Schwabe, C; Stamm, LM; Stedman, CA; Svarovskaia, E; Yang, Y | 1 |
| Brainard, DM; Doehle, BP; Dvory-Sobol, H; Lawitz, EJ; Link, JO; McNally, J; Miller, MD; Mo, H; Worth, AS | 1 |
| Afdhal, N; Bräu, N; Foster, GR; Henry, L; Hunt, S; Mangia, A; Nader, F; Patel, K; Reau, N; Roberts, SK; Stepanova, M; Sulkowski, M; Younossi, ZM | 1 |
| Beavers, K; Bernstein, D; Brainard, DM; Chung, RT; Davis, M; Dvory-Sobol, H; Etzkorn, K; Everson, G; Gane, EJ; Gordon, SC; Khalid, O; Kowdley, KV; Kwo, PY; Lu, S; McHutchison, JG; Nguyen, MH; Poulos, JE; Pound, D; Rodriguez-Torres, M; Stamm, LM; Stedman, CA; Tong, M; Tsai, N; Yang, JC | 1 |
| Bennett, M; Brainard, DM; Curry, M; Dvory-Sobol, H; Hawkins, T; Herring, R; Hinestrosa, F; Jacobson, I; Lawitz, E; Lu, S; McHutchison, JG; Nahass, R; Pearlman, B; Rabinovitz, M; Reau, N; Reddy, KR; Schiff, E; Sheikh, A; Shiffman, M; Stamm, LM; Tran, T; Yang, JC; Younes, Z | 1 |
| Aspinall, RJ; Brainard, DM; Dore, GJ; Feld, JJ; Foster, GR; Fox, R; Grebely, J; Han, L; Mangia, A; McNally, J; Natha, M; Osinusi, A; Subramanian, GM; Sulkowski, M; Zeuzem, S | 1 |
| Chahine, EB; Hemstreet, BA; Sucher, AJ | 1 |
| Greig, SL | 1 |
| Charlton, M; Curry, MP; Feld, J; Foster, GR; Henry, L; Hunt, S; Mangia, A; Nader, F; O'Leary, JG; Stepanova, M; Sulkowski, M; Younossi, ZM; Zeuzem, S | 1 |
| Brainard, D; German, P; Han, L; Kearney, BP; Ling, J; Link, J; Mathias, A; McNally, J; Mogalian, E; Yang, CY | 1 |
| Brainard, DM; Dvory-Sobol, H; Gutierrez, J; Hyland, RH; Landaverde, C; Lawitz, E; McHutchison, JG; Poordad, F; Stamm, LM; Wells, J; Yang, Y | 1 |
| Ibdah, JA; Kahveci, AS; Mir, F; Tahan, V | 1 |
| Adeyemi, O; Brainard, DM; Bräu, N; Daar, ES; Doehle, B; Huang, KC; Kim, AY; Kottilil, S; Luetkemeyer, A; McHutchison, JG; McNally, J; Mogalian, E; Naggie, S; Osinusi, A; Ruane, P; Sulkowski, M; Workowski, K; Wyles, D | 1 |
| Agarwal, K; Asselah, T; Berg, T; Bhandari, BR; Borgia, SM; Brainard, DM; Bräu, N; Davis, M; Dore, GJ; Dvory-Sobol, H; Feld, JJ; Foster, GR; Gane, EJ; Hyland, RH; Jacobson, IM; Lawitz, E; McHutchison, JG; Nahass, RG; Pearlman, B; Roberts, SK; Ruane, PJ; Shafran, SD; Stamm, LM; Stedman, CAM; Subramanian, GM; Svarovskaia, E; Thompson, AJ; Willems, BE; Workowski, KA; Zhu, Y | 1 |
| Brown, RS; Charlton, M; Curry, MP; Hunt, S; O'Leary, JG; Stepanova, M; Younossi, ZM | 1 |
| Gonzalez-Estrada, A; Sankhyan, P | 1 |
| Bansal, MB; Bourlière, M; Brainard, DM; Buggisch, P; Cooper, CL; Curry, MP; de Lédinghen, V; Dvory-Sobol, H; Flamm, SL; Gordon, SC; Huang, KC; Hyland, RH; Kowdley, KV; Landis, CS; Manns, MP; McHutchison, JG; Pianko, S; Ramji, A; Ravendhran, N; Reddy, KR; Schiff, ER; Stamm, LM; Strasser, SI; Subramanian, GM; Svarovskaia, E; Tong, M; Tran, TT; Verna, EC; Vierling, JM; Younes, ZH; Zeuzem, S; Zhang, J | 1 |
| Hussar, DA | 2 |
| Jacobson, IM; Voaklander, R | 1 |
| Arias, A; Barreiro, P; Benítez-Gutiérrez, L; Carrasco, I; de Mendoza, C; Peña, JM; Soriano, V | 1 |
| Asselah, T; Bourgeois, S; Brainard, DM; Feld, JJ; Foster, GR; Gane, EJ; Han, L; Mangia, A; McNally, J; Osinusi, A; Pianko, S; Subramanian, GM; Sulkowski, M; Zeuzem, S | 1 |
| Abergel, A; Asselah, T; Brainard, DM; Camus, G; Dvory-Sobol, H; Han, B; Hsieh, D; Kersey, K; Lu, J; Martin, R; Miller, MD; Mo, H; Parhy, B; Svarovskaia, E | 1 |
| Birnkrant, D; Chan-Tack, K; Naeger, LK; Qi, K; Struble, K | 1 |
| Aschenbrenner, DS | 1 |
| Bhardwaj, N; Brainard, D; Chang, S; Chodavarapu, K; Feld, JJ; Mangia, A; Martin, R; McNally, J; Miller, MD; Mo, H; Murrell, B; Osinusi, A; Ragonnet-Cronin, M; Sulkowski, M; Svarovskaia, ES; Wertheim, JO | 1 |
| Chahine, EB; Childs-Kean, LM; Kelley, D | 1 |
| Clark, A; Dusheiko, G; Fathi, H; Hill, NR | 1 |
| Bourliere, M; Cooper, C; Flamm, S; Gordon, S; Hunt, S; Jacobson, I; Kowdley, K; Mann, MP; Reddy, KR; Stepanova, M; Younossi, I; Younossi, ZM; Zeuzem, S | 1 |
| Asselah, T; Foster, GR; Gane, EJ; Henry, L; Jacobson, IM; Lawitz, E; Pearlman, B; Racila, A; Roberts, SK; Stepanova, M; Thompson, AJ; Welzel, TM; Willems, BE; Younossi, I; Younossi, ZM | 1 |
| Besandre, R; Liu, HW | 1 |
| Brainard, DM; Doehle, BP; Dvory-Sobol, H; Hedskog, C; Hezode, C; McNally, J; Miller, MD; Mo, H; O'Leary, JG; Osinusi, A; Reau, N; Roberts, SK; Shafran, SD; Shanmugam, R; Svarovskaia, ES; Zeuzem, S | 1 |
| Elhenawee, M; Hashem, H; Ibrahim, AE; Saleh, H | 1 |
| Amin, J; Applegate, TL; Bruggmann, P; Bruneau, J; Byrne, J; Conway, B; Cooper, C; Cunningham, EB; Dalgard, O; Dillon, JF; Dore, GJ; Dunlop, A; Feld, JJ; Fraser, C; Gane, E; Grebely, J; Hajarizadeh, B; Hellard, M; Kronborg, I; Lacalamita, M; Litwin, AH; Marks, P; Matthews, GV; Powis, J; Quiene, S; Read, P; Shaw, D; Siriragavan, S; Swan, T; Thurnheer, MC; Weltman, M | 1 |
| Younossi, ZM | 1 |
| Danta, M; Sanagapalli, S | 1 |
| Bittermann, T; Weinberg, E | 1 |
| Boglione, L; Cariti, G; Di Perri, G; Lupia, T; Pinna, SM | 1 |
| Bukh, J; Fahnøe, U; Gottwein, JM; Li, YP; Pedersen, J; Pham, LV; Ramirez, S | 1 |
| Muir, A; Wilder, JM | 1 |
| Brainard, DM; Curtis, C; Lasseter, K; Lawitz, E; Ling, KHJ; Marbury, T; Mathias, A; Mogalian, E; Moorehead, L; Murray, B; Osinusi, A; Perry, R | 1 |
| Brainard, DM; Ling, KHJ; Mathias, A; Mogalian, E; Osinusi, A; Shen, G; Stamm, LM | 1 |
| Baumgarten, A; Boesecke, C; Busch, HW; Christensen, S; Daeumer, M; Hueppe, D; Ingiliz, P; Luebke, N; Lutz, T; Mauss, S; Rockstroh, JK; Sarrazin, C; Schewe, K; Schulze Zur Wiesch, J; Simon, KG; Timm, J; Vermehren, J; von Felden, J | 1 |
| Deeks, ED; Heo, YA | 1 |
| Cory, TJ; Gong, Y; Kodidela, S; Kumar, S; Mu, Y | 1 |
| Waked, I | 1 |
| Bourlière, M; Brainard, DM; Curry, MP; Dvory-Sobol, H; Gordon, SC; Hyland, RH; Landis, CS; Manns, MP; McHutchison, JG; Ravendhran, N; Reddy, KR; Schiff, ER; Sepe, TE; Serfaty, L; Stamm, LM; Subramanian, GM; Thompson, AJ; Tran, TT; Zhang, J | 1 |
| Summers, BB | 1 |
| Sadler, MD | 1 |
| Christensen, S; Sarrazin, C; Schulze Zur Wiesch, J; Vermehren, J; von Felden, J | 1 |
| Agarwal, K; Arterburn, S; Brainard, DM; Camus, G; Castells, L; Dufour, JF; Forns, X; Mani Subramanian, G; Mariño, Z; McNabb, B; McNally, J; Müllhaupt, B; Rosenberg, WMC; Stamm, LM | 1 |
| Bourliere, M; Gordon, SC; Manns, MP; Racila, A; Reddy, R; Schiff, E; Stepanova, M; Tran, T; Younossi, I; Younossi, ZM | 1 |
| Brainard, DM; Camus, G; Chayama, K; De-Oertel, S; Enomoto, H; Ide, T; Ikeda, F; Izumi, N; Jiang, D; Kakizaki, S; Kawakami, Y; Kurosaki, M; McHutchison, JG; McNabb, BL; Mizokami, M; Mochida, S; Stamm, LM; Takaguchi, K; Takehara, T; Tanaka, Y; Toyoda, H; Ueno, Y; Yatsuhashi, H | 1 |
| Basile, M; Cicchetti, A; Coretti, S; Drago, C; Rolli, FR; Romano, F; Ruggeri, M | 1 |
| Badr, KA; Basalious, EB; Rezk, MR | 1 |
| Chakraborty, S; Garlapati, P; Gayam, V; Gill, A; Guss, D; Khalid, M; Mandal, AK; Mansour, M; Mohanty, S; Mukhtar, O; Sherigar, J; Shrestha, B; Tiongson, B | 1 |
| Bourliere, M; Brainard, DM; Camus, G; Cooper, CL; Doehle, BP; Dvory-Sobol, H; Flamm, SL; Gordon, SC; Hyland, RH; Kowdley, KV; Manns, MP; Martin, R; Mo, H; Reddy, KR; Roberts, SK; Sarrazin, C; Stamm, LM; Svarovskia, E; Zeuzem, S | 1 |
| Abdel-Lateef, MA; Ali, R; Derayea, SM; Omar, MA | 1 |
| Bischoff, J; Rockstroh, JK | 1 |
| Jacobson, IM | 1 |
| Kottilil, S; Mathur, P; Wilson, E | 1 |
| Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Chen, EQ; Deng, R; Lv, DD; Tang, H; Tao, YC; Wang, ML; Wang, YH; Yuan, M | 1 |
| Hinds, AE; Pearlman, BL | 1 |
| Gragnani, L; Monti, M; Zignego, AL | 1 |
| Amin, J; Applegate, TL; Bruggmann, P; Bruneau, J; Conway, B; Cooper, C; Cunningham, EB; Dalgard, O; Dillon, JF; Dore, GJ; Dunlop, AJ; Feld, JJ; Fraser, C; Gane, E; Grebely, J; Hajarizadeh, B; Hellard, M; Litwin, AH; Marks, P; Matthews, GV; Norton, B; Powis, J; Quiene, S; Read, P; Shaw, D; Siriragavan, S; Thurnheer, MC; Weltman, M | 1 |
| Chen, B; Chen, EQ; Jiang, W; Tang, H; Tao, YC; Wang, ML; Wang, YH; Wu, DB | 1 |
| Bou Daher, H; Koussa, S; Marrache, M; Rimmani, HH; Rustom, LBO; Sharara, AI; Taher, A | 1 |
| Angelidakis, G; Blechacz, B; Economides, MP; Granwehr, BP; Hosry, J; Jiang, Y; Kaseb, A; Kyvernitakis, A; Mahale, P; Miller, E; Naing, A; Raad, II; Samaniego, F; Torres, HA | 1 |
| Brainard, DM; McHutchison, JG; Stamm, LM | 1 |
| Cenderello, G; Di Biagio, A; Taramasso, L | 1 |
| Abdurakhmanov, D; Bakulin, I; Brainard, DM; Burnevich, E; Chulanov, V; Gankina, N; Hyland, RH; Isakov, V; Ivashkin, V; Kozhevnikova, G; Lagging, M; Lu, S; McNally, J; Morozov, V; Nurmukhametova, E; Romanova, S; Svarovskaia, ES; Weiland, O; Zhdanov, K; Zhuravel, S | 1 |
| Chen, X; Deng, H; Hu, C; Huang, H; Li, W; Li, Y; Liu, J; Peng, Y; Ren, Y; Wu, T; Yuan, G; Zhang, YY; Zhou, Y | 1 |
| Muljono, DH | 1 |
| Begovac, J; Bogdanić, N; Krznarić, J; Močibob, L; Zekan, Š | 1 |
| Kimura, K | 1 |
| Brainard, DM; Dvory-Sobol, H; Gane, EJ; Hyland, RH; Nyberg, L; Ruane, P; Shafran, S; Shao, J; Stamm, LM; Strasser, SI; Tran, T | 1 |
| Asahina, Y; Doi, A; Hikita, H; Kai, Y; Kato, T; Kodama, T; Murayama, A; Nakabori, T; Nitta, S; Saito, Y; Sakamori, R; Suemizu, H; Tahata, Y; Takehara, T; Tatsumi, T; Yamada, R | 1 |
| Marzouk, HM; Monir, HH; Rezk, MR | 1 |
| Althoff, CE; Bergfeld, L; Brakemeier, S; Budde, K; Duerr, M; Eckardt, KU; Glander, P; Halleck, F; Lehner, LJ; Marticorena Garcia, SR; Sack, I; Schrezenmeier, EV | 1 |
| Baden, LR; Camp, PC; Chen, K; Coppolino, A; Fanikos, J; Givertz, MM; Goldberg, HJ; Haddad, EA; Harrington, DP; Johnson, ME; Kusztos, AE; Mallidi, HR; Mehra, MR; Singh, SK; Woolley, AE | 1 |
| Douglas, MW; Eden, JS; George, J; Tay, ES | 1 |
| Cenderello, G; Ciancio, A; Copetti, M; Lorusso, C; Mangia, A; Minisini, R; Orlandini, A; Piazzolla, V; Santoro, R; Squillante, MM; Verucchi, G | 1 |
| Beran, RK; Cheng, G; Dvory-Sobol, H; Han, B; Lu, J; Martin, R; Mo, H; Svarovskaia, E; Yu, M | 1 |
| Aghemo, A; Parigi, TL; Torres, MCP | 1 |
| Angulo-Diaz, V; Lim, JK; Mandimika, C; Maughan, A; Ogbuagu, O; Sadigh, K; Villanueva, M | 1 |
| Hinds, A; Pearlman, B; Perrys, M | 1 |
| Agostinacchio, E; Carraturo, I; Cela, M; Chimenti, A; Copetti, M; Cuccorese, G; De Gioia, S; Giannelli, A; Lauletta, G; Losappio, R; Mangia, A; Mazzola, M; Mennea, G; Metrangolo, A; Minerva, N; Napoli, N; Palmieri, V; Piazzolla, V; Piccigallo, E; Potenza, D; Sabbà, C; Santoro, R; Tagarielli, V; Visaggi, E | 1 |
| Amador, J; Di Bisceglie, AM; Evon, DM; Fried, MW; Golin, CE; Lim, JK; Lok, AS; Nelson, DR; Rajender Reddy, K; Reau, N; Reeve, BB; Sarkar, S; Serper, M; Sterling, RK; Stewart, PW | 1 |
| Bwa, AH; Hlaing, NKT; Kyaw, AMM; Lin, S; Loza, BL; Maung, MZ; Maung, ST; Myint, KT; Nangia, G; Reddy, KR; Sein Win, S; Tun, KT; Win, KM | 1 |
| Coppola, N; Onorato, L; Pisaturo, M; Russo, A | 1 |
| Chua, J; Comstock, E; Covert, E; Emmanuel, B; Hoffmann, J; Husson, J; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; Price, A; Rosenthal, E; Tang, L; Wilson, E | 1 |
| Agarwal, K; Ampuero, J; Ben-Ari, Z; Borgia, SM; Brown, A; Bruck, R; Calleja, JL; Cooper, C; Cramp, ME; Dearden, J; Dvory-Sobol, H; Esteban, R; Fox, R; Foxton, M; Gane, EJ; Haider, S; Hyland, R; Kirby, BJ; Lu, S; Lurie, Y; Markova, S; Meng, A; Osinusi, AO; Rodriguez, CF; Ryder, SD; Shafran, SD; Shaw, D; Willems, B; Yoshida, EM | 1 |
| Cooke, G; Fawsitt, CG; Vickerman, P; Welton, NJ | 1 |
| Antonio Carrión, J; Arenas, J; Arencibia, A; Badia, E; Bernal, V; Buti, M; Cachero, A; Carmona, I; Conde, I; Delgado, M; Diago, M; Esteban, R; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; García-Samaniego, J; Gea, F; González-Santiago, JM; Hernández-Guerra, M; Iñarrairaegui, M; Lens, S; Llaneras, J; Llerena, S; Luis Calleja, J; María Morillas, R; Mariño, Z; Montoliu, S; Pascasio, JM; Riveiro-Barciela, M; Rosales, JM; Torras, X; Turnes, J | 1 |
| Asselah, T; Bourgeois, S; Brainard, DM; Davis, MN; Huang, KC; Lai, CL; Mathurin, P; McNally, J; Nguyen, MH; Osinusi, A; Shafran, SD; Shaikh, OS; Svarovskaia, E; Tran, TT; Willems, B | 1 |
| Awad, J; Balsara, K; Brinkley, DM; Brown Sacks, S; Danter, M; Darragh, C; Fowler, R; Lindenfeld, J; Menachem, J; O'Dell, H; Ooi, H; Perri, R; Punnoose, L; Ruzevich-Scholl, S; Schlendorf, K; Shah, A; Smith, S; Wigger, M; Zalawadiya, SK | 1 |
| Bahuguna, P; Chugh, Y; Dhiman, RK; Premkumar, M; Prinja, S; Singh Grover, G | 1 |
| Andreoni, M; Aragri, M; Cerva, C; Ferrari, L; Foroghi Biland, L; Gentile, A; Malagnino, V; Salpini, R; Sarmati, L; Svicher, V; Teti, E | 1 |
| Cariti, G; Di Perri, G | 1 |
| Mandimika, C; Ogbuagu, O | 1 |
| Asghar, S; Hussain, T; Irfan, M; Khalid, I; Khalid, SH; Khan, IU; Mehmood, Y; Shahzad, Y; Yousaf, AM | 1 |
| Barclay, ST; Boyle, A; Datta, S; Heydtmann, M; Marra, F; Peters, E; Priest, M; Ritchie, T | 1 |
| Chung, RT; Holmes, JA | 1 |
| Heinz, A; Johnson, NL; Lasser, KE; Lee, KS; Quintiliani, L; Truong, V; Xuan, Z | 1 |
| Althoff, KN; Elion, RA; Eron, JJ; Gillman, J; Huhn, GD; Jayaweera, DT; Mills, A; Mounzer, K; Moyle, G; Patel, SV; Radtchenko, J; Santiago, S; Sax, PE | 1 |
| Brennfleck, FW; Brunner, SM; Evert, K; Junger, H; Knoppke, B; Melter, M; Schlitt, HJ; Weigand, K | 1 |
| Ding, Y; Kersey, K; Li, C; Li, X; Shen, G; Zhang, H; Zhu, X | 1 |
| Chen, YW; Wong, KY; Yiu, CB | 1 |
| Guyader, D; Jézéquel, C; Lalanne, S; Lemaitre, F; Mercerolle, M; Pronier, C; Tron, C; Verdier, MC | 1 |
| Asselah, T; Bailly, F; Combis, JM; Dumortier, J; Glorian-Petraud, D; Guyader, D; Heluwaert, F; Hézode, C; Larrey, D; Leroy, V; Libert, O; Ouzan, D; Pol, S; Ramroth, H; Remy, AJ; Riachi, G; Roche, B; Rosa, I; Roulot, D; Thabut, D; Thiefin, G; Truchi, R | 1 |
| Khodarahmi, R; Sayad, B; Sobhani, M | 1 |
| Barnes, E; Chau, NVV; Cooke, GS; McCabe, L; Pett, SL; Walker, AS; White, IR | 1 |
| Borgia, SM; Brown, RS; Carrat, F; Doucette, K; Fagiuoli, S; Khalili, M; Lampertico, P; Losappio, R; Mangia, A; Mertens, M; Milligan, S; Ntalla, I; Ouzan, D; Papatheodoridis, G; Pérez-Hernandez, F; Ramji, A; Ramroth, H; Shafran, SD; Turnes, J; Vanstraelen, K; Wedemeyer, H; Wick, N | 1 |
| Barnes, E; Magri, A; Nguyen, D; Simmonds, P; Smith, D; Vaughan-Jackson, A | 1 |
| Izzi, A; Maggi, P; Messina, V; Rinaldi, L | 1 |
| Da, BL; Dieterich, D; Kushner, T; Lourdusamy, V; Saberi, B | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Liu, CH; Liu, CJ; Su, TH | 1 |
| Aikata, H; Chayama, K; Fukuhara, T; Hayes, CN; Imamura, M; Mori, N; Ohya, K; Takaki, S; Tsuji, K; Yamaguchi, S | 1 |
| Forns, X; García-Samaniego, J; Lens, S; Mateos-Muñoz, B; Miquel, M | 1 |
| Rodriguez-Reyes, M; Ruiz-Boy, S; Sotoca-Momblona, JM | 1 |
| Shi, L; Sun, X; Yun, H; Zhao, G | 1 |
| Ahlenstiel, G; Bowden, S; Dore, GJ; Douglas, M; Doyle, J; Farrell, G; Fisher, L; George, J; Haque, M; Hazeldine, S; Hellard, M; Levy, M; MacQuillan, G; McGarity, B; New, K; O'Beirne, J; O'Keefe, J; Papaluca, T; Prewett, E; Roberts, SK; Sawhney, R; Sievert, W; Sinclair, M; Sood, S; Stoove, M; Strasser, SI; Stuart, KA; Thomas, J; Thompson, AJ; Tse, E; Valaydon, Z; Valiozis, I; Wade, AJ; Weltman, M; Wigg, A; Wilson, M; Woodward, A | 1 |
| Bowyer, S; Bukh, J; Chen, S; Fernandes Campos, GR; Harris, M; Ramirez, S; Ward, JC | 1 |
| Kakizaki, S; Kizawa, K; Kosone, T; Marubashi, K; Sato, K; Shimizu, M; Takagi, H; Takakusagi, S; Uraoka, T; Yokoyama, Y | 1 |
| Bayer, J; Burton, J; Dodge, J; Ghobrial, M; Klein, C; Mohan, S; Niemann, CU; Rubin, RA; Terrault, NA; Trotter, J; Verna, E; Victor, D | 1 |
| Cornberg, M; Deterding, K; Jung, MC; Klinker, H; Manns, MP; Sarrazin, C; Schulze Zur Wiesch, J; Serfert, Y; Simon, KG; Stoehr, A; Teuber, G; Vermehren, J; Wedemeyer, H; Zeuzem, S | 1 |
| De, A; Dhiman, RK; Duseja, A; Kohli, HS; Kumar, V; Mehta, M; Premkumar, M; Ramachandran, R; Ratho, RK; Singh, MP; Singh, V; Taneja, S; Verma, N | 1 |
| Bhakuni, P; Chakrabarti, S; Gupta, M; Jaiswal, SR; Soni, M; Thatai, A | 1 |
| Barrett, BK; Chan, J; Feld, JJ; Hamadeh, A; Kim, JJ; Wong, WWL | 1 |
| Chen, EQ; Chen, XB; Jiang, W; Li, J; Tao, YC; Wang, ML; Wang, YH; Wu, DB; Xiao, GB | 1 |
| Abutaleb, A; Chua, JV; Frumkin, LR; Ghosh, A; Husson, J; Kottilil, S; Lam, KW; Lee, S; Luz Pascual, M; Mutumbi, L; Ntem-Mensah, A; Poonia, B; Romani, S | 1 |
| Chen, SC; Cheng, TS; Chuang, WL; Dai, CY; Hsieh, PH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ | 1 |
| Aluzaite, K; Fraser, M; Giles, H; Johnson, S; Schultz, M | 1 |
| Abdelazim, AH; Attia, KAM; El-Abasawi, NM; El-Olemy, A; Goda, AI; Shahin, M; Zeid, AM | 1 |
| Buonomo, AR; Cattaneo, L; Coppola, C; Coppola, N; De Pascalis, S; Gentile, I; Martini, S; Mercinelli, S; Messina, V; Nerilli, M; Pinchera, B; Scotto, R; Staiano, L; Stanzione, M; Stornaiuolo, G | 1 |
| Abdelazim, AH; Abu-Khadra, AS; Shahin, M | 1 |
| Booth, J; Borgia, SM; Conway, B; Cooper, C; Feld, JJ; Lee, S; Lilly, LB; Morales, H; Onofrio, FQ; Ramji, A; Sattar, I; Vachon, ML; Wong, A | 1 |
| Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, JJ; Huang, KJ; Huang, YJ; Hung, CC; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Yang, SS | 1 |
| Buti, M; Campos, C; Cañizares, A; Carrión, JA; Castro-Iglesias, A; Costa, JG; Esteban, JI; Garcia-Cehic, D; Gregori, J; Macenlle, R; Pamplona, J; Quer, J; Rando, A; Rodriguez-Frias, F; Tabernero, D | 1 |
| Enomoto, M; Fujii, H; Hai, H; Kawada, N; Kozuka, R; Nonomura, A; Tamori, A; Uchida-Kobayashi, S | 1 |
| Afsharian, M; Bozorgomid, A; Janbakhsh, A; Khodarahmi, R; Khosravi Shadmani, F; Mansouri, F; Miladi, R; Mohseni Afshar, Z; Najafi, F; Rahimi, Z; Salimi, M; Sayad, B; Shirvani, M; Vaziri, S; Zamanian, MH | 1 |
| Chiu, YW; Huang, CF; Wei, YJ; Wu, YT; Yu, ML | 1 |
| Barbaliscia, S; Bruzzone, B; Cassol, C; Caudai, C; Ceccherini-Silberstein, F; Coppola, N; Cuomo, N; Di Maio, VC; Micheli, V; Monno, L; Montagnani, F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet, C; Paglicci, L; Paolucci, S; Rossetti, B; Santantonio, T; Zanelli, G; Zazzi, M | 1 |
| Gschwantler, M; Gutic, E; Haltmayer, H; Lang, T; Pirker, R; Reiberger, T; Schmidbauer, C; Schubert, R; Schütz, A; Schwanke, C; Schwarz, M | 1 |
| Chang, KC; Chang, TS; Chen, WM; Hsieh, YY; Huang, YT; Hung, CH; Lu, CK; Lu, SN; Shen, CH; Tung, SY; Wei, KL; Yen, CW | 1 |
| Fraser, H; Havens, JR; Hoven, A; Lofwall, M; Schaninger, T; Staton, M; Vickerman, P; Walsh, SL; Young, AM | 1 |
| Hao, J; Li, C; Li, J; Li, YP; Ma, L; Rao, G; Rong, D; Rong, L; Wang, H; Xiao, F; Yang, Y; Zhang, Z; Zhou, Q; Zhou, Y | 1 |
| Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, KJ; Huang, YJ; Hwang, JJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Wu, JH; Yang, SS | 1 |
| Bloom, DE; Khoury, A; Srinivasan, V | 1 |
| Borgia, SM; Shafran, SD | 1 |
| Chen, R; Li, D; Yuan, X; Zhang, M | 1 |
| Flamm, SL; Martin, MT; Patel, S | 1 |
| Beier, C; Cornberg, M; Kordecki, N; Maasoumy, B; Ohlendorf, V; Sandmann, L; Tergast, TL; Wedemeyer, H | 1 |
| Abdelazim, AH; Abdelzaher, AM; Ramzy, S; Shahin, M | 1 |
| Bansal, S; Giacomet, V; Hsueh, CH; Indolfi, G; Iorio, R; Kelly, D; Kersey, K; Mangia, A; Mania, A; Nebbia, G; Parhy, B; Pawlowska, M; Sang Yue, M; Shao, J; Szenborn, L | 1 |
| Camus, G; Grant, PM; Gupta, N; Kabihizi, J; Kateera, F; Makuza, JD; Manirambona, L; Mukabatsinda, C; Murangwa, A; Musabeyezu, E; Muvunyi, CM; Nsanzimana, S; Serumondo, J; Shumbusho, F | 1 |
| Camus, G; Grant, PM; Gupta, N; Kabakambira, JD; Kabihizi, J; Kateera, F; Makuza, JD; Manirambona, L; Murangwa, A; Muvunyi, CM; Nsanzimana, S; Serumondo, J; Shumbusho, F; Sylvain, H | 1 |
| Adinolfi, LE; De Lucia Sposito, P; Fusco, R; Gaglione, P; Izzi, A; Lumino, P; Maggi, P; Marrone, A; Messina, V; Nevola, R; Rega, R; Rinaldi, L; Sasso, FC; Simeone, F | 1 |
| Jacob, DA; Kolberg, JL; Rumph, DM; Straley, CM | 1 |
| Chen, JJ; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD | 1 |
| Hui, VK; Kao, JH; Kumar, R; Liu, CH; Tan, J; Tan, SS; Thurairajah, PH; Wong, GH; Wong, YJ | 1 |
| Falade-Nwulia, O; Karimi-Sari, H; Lim, JK; Rezaee-Zavareh, MS | 1 |
| Choi, E; Han, DG; Jung, Y; Lee, HY; Park, JE; Song, IS; Yoo, JW; Yoon, IS | 1 |
| Dai, H; Fang, C; Guo, Y; Hu, S; Lan, G; Liu, Q; Nie, M; Peng, F; Peng, L; Tan, L; Xie, X; Zhang, H; Zhong, M | 1 |
22 review(s) available for carbamates and gs-5816
| Article | Year |
|---|---|
Hepatitis C virus NS5A inhibitors and drug resistance mutations.
Topics: Animals; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Mutation; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2014 |
Next-Generation Regimens: The Future of Hepatitis C Virus Therapy.
Topics: Amides; Antiviral Agents; Benzazepines; Benzofurans; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Discovery; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Indoles; Isoquinolines; MicroRNAs; Molecular Targeted Therapy; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Nonstructural Proteins | 2015 |
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins | 2016 |
Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
Topics: Adult; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome | 2017 |
Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.
Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.
Topics: Antiviral Agents; Carbamates; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir | 2017 |
NewDrugs 2017, part 2.
Topics: Amides; Antibodies, Monoclonal, Humanized; Benzofurans; Carbamates; Cyclopropanes; Drug Approval; Drug Therapy; gamma-Cyclodextrins; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Peptides; Phenylalanine; Quinoxalines; Sofosbuvir; Sugammadex; Sulfonamides; Sulfones; Thioglycolates; Triazoles; United States; United States Food and Drug Administration | 2017 |
Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2017 |
Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C.
Topics: Aminoisobutyric Acids; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Tablets; Treatment Outcome | 2017 |
Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations.
Topics: Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles | 2018 |
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Drug Resistance, Viral; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2018 |
Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome | 2018 |
Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sexual and Gender Minorities; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2019 |
Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection.
Topics: Adult; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Fatigue; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nasopharyngitis; Nausea; Pain; Patient Reported Outcome Measures; Sofosbuvir; Tablets; Young Adult | 2018 |
Treatment of hepatitis C virus genotype 4 in the DAA era.
Topics: Aminoisobutyric Acids; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Proline; Quinoxalines; Randomized Controlled Trials as Topic; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2019 |
Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis.
Topics: Antiviral Agents; Carbamates; Controlled Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Female; Hepacivirus; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Prognosis; Randomized Controlled Trials as Topic; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
New approaches in viraemic organ transplantation and antiviral therapies.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Proline; Quinoxalines; Salvage Therapy; Sofosbuvir; Sulfonamides; Tenofovir; Transplants | 2020 |
48 trial(s) available for carbamates and gs-5816
| Article | Year |
|---|---|
A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Placebos; Polymorphism, Single Nucleotide; RNA, Viral; Viral Nonstructural Proteins; Young Adult | 2015 |
Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.
Topics: Adolescent; Adult; Antiviral Agents; Carbamates; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Hepacivirus; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Membrane Transport Proteins; Middle Aged; Young Adult | 2016 |
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Young Adult | 2015 |
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Young Adult | 2015 |
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Recurrence; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2015 |
Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Patient Reported Outcome Measures; Quality of Life; Ribavirin; Sofosbuvir | 2016 |
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; New Zealand; Proline; Protease Inhibitors; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins; Young Adult | 2016 |
Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Mutation; RNA, Viral; Viral Nonstructural Proteins | 2016 |
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
Topics: Adult; Carbamates; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load | 2016 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
Topics: Adult; Antiviral Agents; Carbamates; Data Interpretation, Statistical; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2016 |
Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects.
Topics: Adult; Animals; Antiviral Agents; Carbamates; Dogs; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Macaca fascicularis; Male; Microsomes, Liver; Middle Aged; Rats; Rats, Sprague-Dawley; Viral Nonstructural Proteins; Virus Replication; Young Adult | 2017 |
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Ribavirin; Severity of Illness Index; Sofosbuvir; Sulfonamides; Treatment Outcome; Young Adult | 2017 |
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Female; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Sofosbuvir; United States | 2017 |
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Young Adult | 2017 |
Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Intention to Treat Analysis; Liver Cirrhosis; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2016 |
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins | 2017 |
Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
Topics: Antiviral Agents; Carbamates; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; High-Throughput Nucleotide Sequencing; Humans; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Topics: Administration, Oral; Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Packaging; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Medication Adherence; Middle Aged; Recurrence; Risk Factors; Sofosbuvir; Substance Abuse, Intravenous; Sustained Virologic Response | 2018 |
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Hepatic Insufficiency; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine; Young Adult | 2018 |
Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Interactions; Female; Healthy Volunteers; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Tenofovir; Young Adult | 2018 |
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Treatment Failure; Viral Nonstructural Proteins | 2018 |
Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Linear Models; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Young Adult | 2018 |
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; High-Throughput Nucleotide Sequencing; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Medication Adherence; Middle Aged; Sofosbuvir; Substance Abuse, Intravenous | 2018 |
Sofosbuvir/velpatasvir for chronic hepatitis C infection in patients with transfusion-dependent thalassemia.
Topics: Antiviral Agents; Blood Transfusion; Carbamates; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Sofosbuvir; Thalassemia; Young Adult | 2019 |
Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Russia; Sofosbuvir; Sweden; Young Adult | 2019 |
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Biopsy, Needle; Calcineurin Inhibitors; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Glucose Intolerance; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Liver; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; RNA, Viral; Salvage Therapy; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins; Viremia | 2019 |
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Carbamates; Female; Graft Rejection; Graft Survival; Heart Transplantation; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Heterocyclic Compounds, 4 or More Rings; Humans; Lung Transplantation; Male; Middle Aged; Pilot Projects; RNA, Viral; Sofosbuvir; Tissue Donors | 2019 |
SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study.
Topics: Adult; Aged; Carbamates; Cohort Studies; Comorbidity; Female; Hepacivirus; Heterocyclic Compounds, 4 or More Rings; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Pilot Projects; Proline; Quinoxalines; Recurrence; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Monitoring; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Renal Dialysis; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2019 |
Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Placebos; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; China; Female; Fluorenes; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Sofosbuvir | 2020 |
The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.
Topics: Administration, Oral; Antiviral Agents; Bayes Theorem; Carbamates; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Vietnam | 2020 |
Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open-label study.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Pilot Projects; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors | 2021 |
Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial.
Topics: Adult; Antiviral Agents; Carbamates; COVID-19; Heterocyclic Compounds, 4 or More Rings; Humans; Iran; Pandemics; Prospective Studies; SARS-CoV-2; Sofosbuvir; Standard of Care; Treatment Outcome | 2021 |
Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kentucky; Pregnancy; Sofosbuvir; Treatment Outcome | 2021 |
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Death, Sudden; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Rwanda; Sofosbuvir; Sulfonamides; Treatment Failure | 2022 |
Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial.
Topics: Adolescent; Adult; Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Prospective Studies; Rwanda; Sofosbuvir | 2022 |
112 other study(ies) available for carbamates and gs-5816
| Article | Year |
|---|---|
Sofosbuvir and Velpatasvir: A complete pan-genotypic treatment for HCV patients.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Randomized Controlled Trials as Topic; Sofosbuvir | 2016 |
What does it mean to put new hepatitis C drugs on a list of essential medicines?
Topics: Antiviral Agents; Carbamates; Drug Costs; Drugs, Essential; Health Priorities; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; World Health Organization | 2016 |
[New combination heals still more patients in an even shorter period of time].
Topics: Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir | 2016 |
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Treatment Outcome | 2017 |
Mixed Essential Cryoglobulinemia.
Topics: Antiviral Agents; Carbamates; Cryoglobulinemia; Exanthema; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Immunologic Factors; Male; Middle Aged; Rituximab; Sofosbuvir | 2017 |
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
Topics: Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response | 2018 |
Mavyret and Vosevi--two new combinations for chronic HCV infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome | 2017 |
Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4.
Topics: Amino Acid Substitution; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; High-Throughput Nucleotide Sequencing; Humans; Sequence Analysis, DNA; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Nonstructural Proteins | 2018 |
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Risk Assessment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2018 |
New Oral HCV Drug.
Topics: Administration, Oral; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Contraindications, Drug; Cyclopropanes; Drug Approval; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2017 |
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Placebos; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Surveys and Questionnaires; Sustained Virologic Response | 2018 |
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Multicenter Studies as Topic; Patient Reported Outcome Measures; Proline; Quinoxalines; Randomized Controlled Trials as Topic; Self Report; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2018 |
Biochemical Basis of Vosevi, a New Treatment for Hepatitis C
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins | 2018 |
Comparison between core-shell and totally porous particle stationary phases for fast and green LC determination of five hepatitis-C antiviral drugs.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Imidazoles; Molecular Conformation; Particle Size; Porosity; Pyrrolidines; Simeprevir; Sofosbuvir; Surface Properties; Valine | 2018 |
New Drugs 2018, part 1.
Topics: Aminoisobutyric Acids; Antibodies, Monoclonal; Antibodies, Neutralizing; Antipyrine; Benzamides; Benzimidazoles; Broadly Neutralizing Antibodies; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Edaravone; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Naltrexone; Natriuretic Peptides; Proline; Pyridines; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration | 2018 |
Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection-Author's reply.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Complete Response of Diffuse Large B Cell Lymphoma After Direct-Acting Antiviral Therapy for Hepatitis C Virus.
Topics: Aged; Antiviral Agents; Carbamates; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Radiography, Abdominal; Ribavirin; Sofosbuvir; Treatment Outcome | 2019 |
Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: a case series.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Liver Cirrhosis; Male; Recurrence; Sofosbuvir; Sustained Virologic Response; Viral Nonstructural Proteins | 2018 |
HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
Topics: Amino Acid Substitution; Antiviral Agents; Benzimidazoles; Carbamates; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Pyrrolidines; Sofosbuvir; Viral Nonstructural Proteins | 2018 |
High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2018 |
Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Retreatment of hepatitis C virus: can it get any better?
Topics: Aminoisobutyric Acids; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides | 2018 |
Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era?
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir | 2018 |
Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply.
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir | 2018 |
Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Italy; Male; Markov Chains; Middle Aged; Patient Acceptance of Health Care; Quality-Adjusted Life Years; Sofosbuvir; Young Adult | 2018 |
Novel determination of sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS method: Application to a bioequivalence study.
Topics: Adult; Carbamates; Chromatography, High Pressure Liquid; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Linear Models; Male; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Sofosbuvir; Tandem Mass Spectrometry; Therapeutic Equivalency; Young Adult | 2018 |
Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Community Health Centers; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2018 |
Study on fluorescence properties of HCV antiviral (velpatasvir) and its fluorimetric determination in presence of sofosbuvir; application to stability study and human plasma.
Topics: Antiviral Agents; Carbamates; Drug Stability; Fluorescence; Fluorometry; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Limit of Detection; Sofosbuvir | 2018 |
Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2018 |
Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Topics: Antiviral Agents; Carbamates; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Registries; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
Topics: Adult; Antiviral Agents; Asian People; Carbamates; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Breast Neoplasms; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Head and Neck Neoplasms; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferons; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
Reply to: "Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL recommendations on treatment of Hepatitis C 2018": EASL Recommendations on Treatment of Hepatitis C 2018: Precision on the tr
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Sofosbuvir | 2019 |
Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Sofosbuvir | 2019 |
Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; China; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2018 |
Effective drugs on the road to HCV elimination and a therapeutic gap to close.
Topics: Asia; Carbamates; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir | 2019 |
Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir: A case report.
Topics: Antiviral Agents; Carbamates; Coinfection; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Renal Dialysis; Sofosbuvir | 2018 |
Long-awaited treatment for hepatitis C virus decompensated cirrhosis.
Topics: Carbamates; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Liver Cirrhosis; Ribavirin; Sofosbuvir | 2019 |
Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Topics: Aged; Animals; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cell Line; Chimera; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Guanosine Monophosphate; Hepacivirus; Hepatitis C; Hepatocytes; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Male; Mice; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sequence Deletion; Serine Proteases; Simeprevir; Valine; Viral Nonstructural Proteins | 2019 |
Spectrophotometric assessment of the brand new antiviral combination: Sofosbuvir and velpatasvir in their pure forms and pharmaceutical formulation.
Topics: Analysis of Variance; Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Drug Compounding; Heterocyclic Compounds, 4 or More Rings; Limit of Detection; Reference Standards; Regression Analysis; Reproducibility of Results; Sofosbuvir; Spectrophotometry | 2019 |
Hepatitis C Virus Genotype 8 Infection-Successful Treatment With Sofosbuvir/Velpatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; Treatment Outcome | 2019 |
In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Drug Resistance, Viral; Genotype; Hepacivirus; Heterocyclic Compounds, 4 or More Rings; Humans; Mutation; Replicon; Viral Nonstructural Proteins | 2019 |
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients.
Topics: Adult; Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Load | 2019 |
Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome | 2019 |
SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbamates; Drug Interactions; Female; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Safety; Sofosbuvir; Treatment Outcome; Young Adult | 2019 |
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Proline; Prospective Studies; Quinoxalines; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2019 |
High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Myanmar; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Markov Chains; Proline; Quinoxalines; Sofosbuvir; State Medicine; Sulfonamides; United Kingdom | 2019 |
Trends in Renal Function Among Heart Transplant Recipients of Donor-Derived Hepatitis C Virus.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Heart Transplantation; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Diseases; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Uridine Monophosphate | 2020 |
Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
Topics: Adult; Antiviral Agents; Carbamates; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; India; Markov Chains; Quality-Adjusted Life Years; Sofosbuvir; Universal Health Insurance | 2019 |
Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case r
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Mutation; Sofosbuvir; Virus Activation | 2019 |
Drug-drug interactions in anti-HCV therapy: a comparison among options available in Italy.
Topics: Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon-alpha; Italy; Polypharmacy; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides | 2019 |
Successful sofosbuvir lead-in monotherapy for the treatment of hepatitis C virus (HCV) infection in a pregnant woman living with HIV.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carbamates; Female; Hepatitis C; Herpes Genitalis; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Sofosbuvir | 2019 |
Development and validation of a stability-Indicating RP-HPLC method for simultaneous estimation of sofosbuvir and velpatasvir in fixed dose combination tablets and plasma.
Topics: Animals; Carbamates; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Stability; Heterocyclic Compounds, 4 or More Rings; Limit of Detection; Plasma; Rats; Reproducibility of Results; Sensitivity and Specificity; Sofosbuvir; Tablets; Tandem Mass Spectrometry | 2019 |
Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis.
Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Scotland; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Odds Ratio; Primary Health Care; Program Evaluation; Reward; Safety-net Providers; Sofosbuvir; Sustained Virologic Response; Young Adult | 2020 |
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2020 |
Living Donor Liver Transplantation From Hepatitis C-Infected Donor to Hepatitis C-Infected Recipient.
Topics: Adult; Antiviral Agents; Carbamates; Child; Fatty Liver; Female; Hepacivirus; Hepatectomy; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Function Tests; Liver Neoplasms; Liver Transplantation; Living Donors; Monitoring, Physiologic; Sofosbuvir; Transplant Recipients; Treatment Outcome; Viral Load | 2020 |
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL
Topics: Benzimidazoles; Betacoronavirus; Carbamates; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Drug Repositioning; Fluorenes; Heterocyclic Compounds, 4 or More Rings; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Nonstructural Proteins; Viral Proteins | 2020 |
Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Drug Monitoring; Female; Half-Life; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Neoplasms; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Tablets | 2020 |
Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Quality of Life; Sofosbuvir; Sustained Virologic Response; Young Adult | 2021 |
Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
Topics: Antiviral Agents; Betacoronavirus; Carbamates; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Heterocyclic Compounds, 4 or More Rings; Humans; Iran; Pandemics; Patient Safety; Pneumonia, Viral; SARS-CoV-2; Sofosbuvir | 2020 |
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
Topics: Africa South of the Sahara; Antiviral Agents; Asia, Eastern; Benzimidazoles; Benzofurans; Carbamates; Drug Resistance, Viral; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Pyrrolidines; RNA-Dependent RNA Polymerase; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2020 |
Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.
Topics: Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; DNA-Directed DNA Polymerase; Drug Therapy, Combination; Heterocyclic Compounds, 4 or More Rings; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Sofosbuvir; Viral Proteins | 2020 |
Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2021 |
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan | 2020 |
Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain.
Topics: Antiviral Agents; Benzimidazoles; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug Repositioning; Fluorenes; Hepatitis B virus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Pandemics; Peptide Hydrolases; Pneumonia, Viral; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus; Spain | 2020 |
Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2021 |
Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China.
Topics: Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir | 2020 |
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Drug Resistance, Viral; Genome, Viral; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Mutation; Phosphorylation; Replicon; Viral Nonstructural Proteins; Virus Replication | 2020 |
Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir.
Topics: Balloon Occlusion; Carbamates; Female; Hepacivirus; Hepatic Encephalopathy; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Middle Aged; Sofosbuvir; Treatment Outcome | 2020 |
Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney; Kidney Transplantation; Linear Models; Liver; Liver Transplantation; Male; Middle Aged; Proof of Concept Study; Prospective Studies; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Viral Load; Viremia | 2021 |
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis.
Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Failure, Chronic; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Renal Dialysis; Sofosbuvir; Sulfonamides; Treatment Outcome | 2021 |
Safety and efficacy of Sofosbuvir and Velpatasvir in children with active hepatitis C virus infection undergoing haploidentical transplantation.
Topics: Antiviral Agents; Carbamates; Child; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; Transplantation, Haploidentical; Treatment Outcome | 2021 |
Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis.
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Infant, Newborn; Liver Cirrhosis; Liver Neoplasms; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine; Young Adult | 2020 |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Quinoxalines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Taiwan; Treatment Outcome; Valine | 2021 |
Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
Topics: Adult; Carbamates; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Successful use of generic direct acting antiviral medications to treat hepatitis C-a New Zealand-wide study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Seropositivity; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; New Zealand; Pyrrolidines; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2020 |
Simultaneous spectrophotometric quantitative analysis of velpatasvir and sofosbuvir in recently approved FDA pharmaceutical preparation using artificial neural networks and genetic algorithm artificial neural networks.
Topics: Antiviral Agents; Carbamates; Heterocyclic Compounds, 4 or More Rings; Humans; Neural Networks, Computer; Sofosbuvir; Spectrophotometry; Tablets | 2021 |
Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'LIver Network Activity' (LINA) cohort update results.
Topics: Adult; Age Distribution; Aged; Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Italy; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response | 2021 |
Application of different chemometric assisted models for spectrophotometric quantitative analysis of velpatasvir and sofosbuvir.
Topics: Antiviral Agents; Carbamates; Heterocyclic Compounds, 4 or More Rings; Least-Squares Analysis; Sofosbuvir; Spectrophotometry; Tablets | 2021 |
Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Canada; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Registries; Salvage Therapy; Sofosbuvir; Sulfonamides | 2021 |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; Sustained Virologic Response; Taiwan | 2021 |
Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Failure; Viral Nonstructural Proteins | 2021 |
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2021 |
Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy.
Topics: Carbamates; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Renal Dialysis; Sofosbuvir | 2021 |
Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Italy; Macrocyclic Compounds; Prevalence; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides | 2021 |
Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.
Topics: Adult; Analgesics, Opioid; Antiviral Agents; Carbamates; Directly Observed Therapy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response | 2021 |
Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Outcome | 2021 |
Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells.
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; Clone Cells; Genotype; Hepacivirus; Heterocyclic Compounds, 4 or More Rings; Humans; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication | 2021 |
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cost of Illness; Disability Evaluation; Drugs, Generic; Female; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; India; International Normalized Ratio; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Sofosbuvir; Young Adult | 2021 |
Reply to: "Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy".
Topics: Carbamates; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Renal Dialysis; Sofosbuvir | 2021 |
Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Treatment Outcome; Young Adult | 2021 |
Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides | 2021 |
[Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Failure; Treatment Outcome | 2022 |
Comparative evaluation of different mathematical models for simultaneous UV spectrophotometric quantitative analysis of velpatasvir and sofosbuvir.
Topics: Antiviral Agents; Carbamates; Heterocyclic Compounds, 4 or More Rings; Least-Squares Analysis; Models, Theoretical; Sofosbuvir; Spectrophotometry | 2022 |
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Child; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2022 |
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19.
Topics: Antiviral Agents; Carbamates; Case-Control Studies; COVID-19 Drug Treatment; Disease Progression; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sofosbuvir; Treatment Outcome | 2022 |
Impact of proton pump inhibitors on sustained virologic response in veterans treated with sofosbuvir/velpatasvir for chronic hepatitis C virus: A retrospective cohort study.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Proton Pump Inhibitors; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Veterans | 2022 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Lipids; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sugars; Sulfonamides; Treatment Outcome | 2022 |
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Treatment Outcome | 2022 |
Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2022 |
A simple and sensitive HPLC-FL method for bioanalysis of velpatasvir, a novel hepatitis C virus NS5A inhibitor, in rat plasma: Investigation of factors determining its oral bioavailability.
Topics: Administration, Oral; Animals; Antiviral Agents; Biological Availability; Carbamates; Chromatography, High Pressure Liquid; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Rats | 2022 |
Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China.
Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Viremia | 2022 |